Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32502444

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Jun
First author
Sato J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Sato J
      type
      Author
    2. name
      Satouchi M
      type
      Author
    3. name
      Itoh S
      type
      Author
    4. name
      Okuma Y
      type
      Author
    5. name
      Niho S
      type
      Author
    6. name
      Mizugaki H
      type
      Author
    7. name
      Murakami H
      type
      Author
    8. name
      Fujisaka Y
      type
      Author
    9. name
      Kozuki T
      type
      Author
    10. name
      Nakamura K
      type
      Author
    11. name
      Nagasaka Y
      type
      Author
    12. name
      Kawasaki M
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Sato J
      type
      Author
    2. name
      Satouchi M
      type
      Author
    3. name
      Itoh S
      type
      Author
    4. name
      Okuma Y
      type
      Author
    5. name
      Niho S
      type
      Author
    6. name
      Mizugaki H
      type
      Author
    7. name
      Murakami H
      type
      Author
    8. name
      Fujisaka Y
      type
      Author
    9. name
      Kozuki T
      type
      Author
    10. name
      Nakamura K
      type
      Author
    11. name
      Nagasaka Y
      type
      Author
    12. name
      Kawasaki M
      type
      Author
    bibliography ids
    1. nci-bib-27f92d83921653c36a1f5e09
    book metadata
    content sha256
    21d87308f20dd731ae453c5ba04e1282e563c85cfcaddafd30f2d0cea60ebfc9
    document type
    citation
    dois
    1. 10.1016/S1470-2045(20)30162-5
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:32502444
    immutable id
    pubmed:32502444@21d87308f20dd731ae453c5ba04e1282e563c85cfcaddafd30f2d0cea60ebfc9
    journal
    abbreviation
    Lancet Oncol
    issn electronic
    1474-5488
    issn print
    1470-2045
    issue
    6
    name
    The Lancet. Oncology
    nlm unique id
    100957246
    pages
    843-850
    volume
    21
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      32502444
      provenance
      batch id
      40d9eae1f1d369f13109
      provider
      NCBI PubMed ESummary
      record sha256
      dfc7309bcfa08a2798963c8b4c05d4062e65bd37617aec3040f57683bb10e51c
      response sha256
      03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
      retrieved at
      2026-09-09T23:47:52.637547+00:00
      publication date
      display
      2020 Jun
      precision
      month
      year
      2020
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Multicenter Study
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/32502444/
      title
      Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.

      Preserved source evidence · Not medical advice